Previous 10 | Next 10 |
Pulmonx Highlights 2022 Partnership with Lung Association Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, has partnered with American Lung Association to provide education to patients and providers...
Approval of First Minimally Invasive Treatment Option in Japan that Helps Patients with Advanced Disease Breathe Easier and Have a Better Quality of Life Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung diseas...
REDWOOD CITY, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 34th Annual Piper Sandl...
The following slide deck was published by Pulmonx Corporation in conjunction with this event. For further details see: Pulmonx Corp (LUNG) Investor Presentation - Slideshow
Summary Pulmonx has an FDA-approved technology to treat severe emphysema. The company estimates its valve treatment is a $12 billion market opportunity. However, adoption has been slow, and suggests the market may be much smaller. After a large crash in the share price, Pu...
Pulmonx Corporation (LUNG) Q3 2022 Earnings Conference Call November 3, 2022 16:30 ET Company Participants Laine Morgan - Investor Relations Glen French - President and Chief Executive Officer Derrick Sung - Chief Financial Officer Conference Call Participa...
Shares of Pulmonx (NASDAQ: LUNG) were crashing 53.7% lower as of 11:36 a.m. ET on Friday. The company announced its third-quarter results after the market closed on Thursday. However, Pulmonx's Q3 performance wasn't the primary culprit behind its stock plunging today. Instead, i...
Pulmonx ( NASDAQ: LUNG ) stock slumped ~53% on Friday after the company cut its FY22 revenue outlook. Net loss widened to -$14.17M, compared to -$10.18M in Q3 2021. Total worldwide revenue grew +1.8% Y/Y to $13.5M, but missed analysts estimates. Operati...
Pulmonx press release ( NASDAQ: LUNG ): Q3 GAAP EPS of -$0.38 beats by $0.01 . Revenue of $13.5M (+1.8% Y/Y) misses by $1.43M . 2022 Financial Outlook Pulmonx is updating its full year 2022 revenue guidance to be in the range of $51.5 million to $52.5 milli...
REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter ended September 30, 2022. ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2024 after the close of trading...
2024-06-23 01:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...